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SUMMARY 
Techniques for preparing four kinds of hydrogel membrane capsules are described. 
In the present process the material being encapsulated remains in its original 
environment in an aqueous suspension. Also, capsule characteristics such as size, 
membrane thickness, pore-size and surface charge can be controlled over a wide 
range. 
INTRODUCTION 
Encapsulation techniques are fmding increasing interest in a variety of areas 
of biotechnology. Enzymes, living ceils, hormones, drugs, adsorbents and other 
bioactive materials can be encapsulated and used in bioreactors, artificial organs, 
controlled drug-release systems, bioseparation systems and etc (Chang, 1972; 
Kondo, 1979; Lira, 1984; Nigam, 1988; Nixon, 1976). Ideally, encapsulation of 
bioactive materials should be carried out in mild conditions and materials employed 
should be inert and non-toxic. However, a number of encapsulation techniques 
utilizing covalent binding hydrogel membranes require harsh conditions such as the 
use of non-aqueous solvents, extremes of pH, or high temperature. Recently 
ionotropic gels have been used for encapsulating bioactive materials under mild 
conditions. 
Lim et al. (1980; 1982; 1984) successfully encapsulated living ceils in poly 
(L-lysine)-alginate capsules. Cells are initially entrapped in calcium-alginate gel 
beads. Calcium ions in the outer skin of the beads are displaced by poly (L-lysine) 
to form a polyelectrolyte complex membrane and calcium alginate gel thus wrapped 
by the complex is liquified using a calcium chelating agent. Difficulties in 
reproducing the complicated procedures of microencapsulation and in scale-up may 
restrict the extension of this method to a variety of applications. 
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Spiekermann et  a/.(1987) and Klein et  al. (1986) described a simplified 
method for encapsulating living cells in calcium-alginate capsules. In this method 
cells are not suspended in an alginate solution but in a calcium chloride solution. 
Droplets of calcium chloride solution containing cells are dropped into alginate 
solution and then instantly wrapped with calcium-alginate gel membrane. This 
method ensures that bioactive materials to be encapsulated never come into contact 
with the ionotropic gel-forming polymers and stay within their original 
environment. In addition to the simplicity of the procedures in comparison with the 
previous method (Lira et  al., 1980; 1982; 1984), this method may also have the 
advantages of controlling and reproducing various characteristics of the hydrogel 
membrane such as thickness, pore-size, surface charge, mechanical properties and 
others by varying reaction time of capsule formation, alginate and/or calcium ion 
concentration(s) and employing different kinds of gel-forming polymer. 
In this article techniques for preparing several new types of membrane 
capsules using different hydrogels are described. All of these techniques use mild 
conditions suitable for encapsulating even the most delicate bioz~cfive materials such 
as animal cells. The capsules were formed using both single gel-forming polymer 
or a combination of several gel-forming polymers. Gel-forming polymers employed 
in this technique include alginate, agarose and chitosan. However the general 
methodology described can be easily extended to include a wide variety of other 
similar gel-forming polymers. 
MATERIALS AND METHODS 
Preparation of Calcium-Alginate Capsules: Calcium-alginate capsules were 
prepared using a simple one-step process similar to the one described by Spikerman 
et. al. (1987) and Klein et al. (1986). A solution containing 0.5% (w/v) sodium 
alginate (Kelco Gel LV) is prepared (Solution A). An another solution containing 
1.3% (w/v) calcium chloride and 20% (w/v) dextran (M.W. 40,000 ; Sigma) is 
prepared (Solution B), where dextran serves as a non-gelling polymer which is 
used to modulate the viscosity and density of Solution B to ensure spherical shape 
of capsules. It diffuses out of the capsule after the encapsulation is complete. 
Droplets of Solution B are dropped through a hypodermic needle into rapidly stirred 
Solution A. A capsular membrane forms instantaneously around the droplet due to 
the cross-linking of the interfacial alginate molecules by calcium cations. Prior to 
the removal of capsules Solution A is diluted more than five-fold by adding 
required amount of distilled water or appropriate buffer. This step dilutes the 
alginate solution outside the capsules and reduces the possibility of capsules joining 
each other when they are in close contact. The capsules are transferred to a 1.3% 
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(w/v) calcium chloride solution and incubated to stabilize the gel membrane. 
Preparation of Chitosan Capsules: Chitosan forms an ionotropic gel similar to the 
one formed by alginate. However chitosan is a cationic polymer and requires 
negatively charged muhivalent ions (eg. polyphosphate ions) to form the gel 
structure. A solution containing 1.0% (w/v) chitosan (Sigma) and 1.4% (v/v) 
acetic acid is prepared (Solution C). Also, a solution containing 1.5% (w/v) 
sodium-tri-poly-phosphate solution and 40% (w/v) dextran (Sigma) is prepared 
(Solution D). Droplets of the latter solution are dropped into Solution C. A 
chitcrsan polyphosphate membrane is instantly formed enclosing the droplet. 
Capsules are removed from the chitosan solution and further treated in 1.5% (w/v) 
sodium-tri-poly-phosphate solution for half hour after washing away excess 
chitosan using 1.4 % (v/v) acetic acid. 
Preparation of Alginate/Poly (L-lysine) Capsules: The basic approach to making 
capsules described in this paper can be adapted to produce the same type of capsule 
as proposed by Lira et al. (1980; 1982; 1984). This not only simplifies the 
manufacturing procedure but also allows the bioactive material to remain in its 
original environment obviating the need to suspend it in the alginate solution. The 
exterior surface of calcium-alginate capsules prepared by the method described 
earlier is modified by treating with a 0.05% (w/v) poly (L-lysine) solution for 1 
minute. The treated capsules are washed to remove uncomplexed poly (L-lysine). 
Preparation of Ag,'u'ose Capsules: In this preparation alginate is used as a template 
to form the agarose membrane. A solution containing 1.0 % (w/v) agarose (Type 
VII, Sigma A) and 0.25% (w/v) sodium alginate (Type IV, Sigma) is prepared and 
kept around 40 ~ with stirring. An solution containing 1.3% (w/v) calcium 
chloride and 20% (w/v) dextran (Sigma) is also prepared. When the latter solution 
is dropped into the former solution, a capsular membrane is instantly formed 
around the droplet due to the cross-linking of the calcium-alginate gel. The 
capsules thus formed are recovered and washed using prewarmed water at around 
40~ to remove excess polymer solution. The capsules are subsequently cooled in 
water containing 1.3% (w/v) calcium chloride which allows agarose entrapped 
within the membrane to solidify. The capsules are then equilibrated in a buffer 
containing 0.05M EDTA, which is calcium ion chelating agent, to liquify the 
alginate component of the membrane. Since agarose forms gels primarily through 
hydrogen bonding mechanism, these capsules remain stable in solutions containing 
high concentrations of NaCI, EDTA, Phosphate etc. 
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RESULTS AND DISCUSSION 
The present process ensures that most of materials to be encapsulated never 
come in contact with the gel forming polymers, which suggests that this process is 
quite suitable for the encapsulation of bioactive materials. Toxic effects arising out 
of direct contact with charged polymers may affect the viability and growth of 
animal cells (Gharapetian et al.; 1986). Charged polyelectrolytes can also interfere 
with the functioning of bioactive materials such as enzymes by complexing with 
multivalent ions which may serve as cofactors. 
Though calcium-alginate capsules can be produced by quite a simple 
procedure, in some applications capsules made of only calcium-alginate may not be 
suitable because of their instability in the presence of calcium sequestering agents 
such as phosphate, EDTA or high concentrations of monovalent cations. One way 
to overcome this problem is to modify these to alginate/poly (L-lysine) capsules or 
to form an entirely new type of gel capsule such as agarose capsules by the manner 
described in this :u-ticle. 
In a number of applications the capsule properties such as size, membrane 
thickness and pore-size may be manipulated to control the transport kinetics within 
the capsules. In the case of monoclonal antibody production using encapsulated 
hybridoma cells there may be advantages in selecting a pore-size which restricts the 
antibcxty within the capsule allowir~g the yield of antibody in a highly concentrated 
form (Lira, 1984). In our laboratory viable human carcinoma (KB) cells have been 
successfully encapsulated in using this method. Figure 1 shows a photomicrograph 
which demonstrates that encapsulated KB cells remain viable and show normal 
growth till tissue density. We are also able to grow monkey kidney cells (BSC-1) 
on microcarriers CCytodex I, Pharmacia) inside the calcium-alginate membrane 
capsules (Figure 2). Similarly applications involving encapsulated enzymes or 
antibc• require that the substrate or antigen may diffuse freely through the 
membr,me while enzyme or antibody is retained inside the capsule. In applications 
for bioseparation fine particles of ion-exchange resins (DEAE Trisacryl) were 
encapsulated within calcium-alginate membrane and used to isolate and purify 
recombinant 13-1actamase from crude E. coli homogenate (Nigam et al., 1988). 
Also, use of membr,me encapsulated water-soluble polymer-ligand conjugates for 
bioseparation was described using Blue Dextran to isolate and purify human serum 
albumin IFigure 3) (Sakoda et al., 1988). 
A number of capsule characteristics can be very easiiy controlled using 
techniques described in this paper. The size of capsules can be varied from about 
100 micron.~ to a few millimeters in diameter by using a microdroplet generator in 
x~ h;ch the ori|'it c d:ameter and the air flow rate can be varied (Klein et al., 1983). 
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The choice of membrane thickness should be carefully made to optimize its 
opposing effects on the capsule strength and the diffusional resistance. Also, the 
control of membrane thickness during the encapsulation process is essential for 
reproducing uniform capsules. In case of calcium-alginate capsules the thickness of 
gel membrane increases as the residence time of the droplet in the alginate solution 
increases due to the outward diffusion of calcium ion serving as a gelling inducer. 
The final membrane thickness is dependent on the capsule size, concentration of the 
gelling inducer and concentration of the polymer solution. By selecting appropriate 
conditions the membrane thickness can be very conveniently varied between 50 I.tm 
to several hundred micrometers. The pore size of the membrane can be varied over 
a wide range of molecular weight cut-offs depending on the polymer employed and 
its concentration. Calcium-alginate gel in the range of 0.5 to 4 % has a relatively 
smaller pore-size which can severely restrict the diffusion of proteins even in the 
molecular weight range of 60,000 to 100,000 (Tanaka et al.; 1984, Tramper; 1983) 
On the other hand agarose forms relatively porous gel in the range of 2 to 6 %, 
which allows minimal diffusional resistance even to the largest of enzymes 
(Tramper; 1983). By judicious choice of different polymers or their combinations it 
should be possible to tailor the capsule pore-size over a very wide range. 
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Figure 1 Grouth of KB ceils in aIginate/poly 
(L-lysine) capsules 
Figure 2 Monkey Kidney cells (BSC-1) on rnicrocarriers 
inside a calcium-alginate capsle 
Figure 3 Uniform calcium-alginate capsules containing Blue Dextran solution 
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